Skip to main content
Top
Published in: Journal of Endocrinological Investigation 3/2015

01-03-2015 | Original Article

Interleukin-6, soluble interleukin-6 receptor/interleukin-6 complex and insulin resistance in obese children and adolescents

Authors: G. De Filippo, D. Rendina, F. Moccia, V. Rocco, A. Campanozzi

Published in: Journal of Endocrinological Investigation | Issue 3/2015

Login to get access

Abstract

Background/aim

To study the characteristics of interleukin 6 (IL6), soluble form of interleukin 6 receptor (sILR)/IL6 complex in obese children and adolescents and its relationship with insulin resistance (IR).

Subjects and methods

66 obese children and adolescents [34 boys, mean age 10.3 ± 2.9 years, z-score of body mass index (BMI) 4.76 ± 1.36] and 24 non-obese healthy sex- and age-matched controls. Fasting levels of glucose, insulin, IL6, sIL6, sgp130 were measured. IR was assessed by homeostasis model assessment of IR (HOMA-IR).

Results

Obese subjects showed increased levels of insulin and IL-6 and higher HOMA-IR compared to controls (117.67 ± 50.9 vs. 62.42 ± 29.4 pmol/L, 2.73 ± 0.98 vs. 1.07 ± 0.41 pg/ml and 4.03 ± 2.16 vs. 1.83 ± 1.05 for insulin, IL-6 and HOMA-IR, respectively, p < 0.01 in all cases). sIL-6R levels were significantly lower in obese subjects (34.7 ± 14.2 vs. 55.6 ± 15.2 ng/ml in controls, p = 0.005), whereas sgp130 levels were not significantly different. In obese subjects, IL-6 directly correlated with z-score BMI (r = 0.481, p = 0.009) and with waist-to-height ratio (r = 0.494, p = 0.007), while sIL6-R was inversely related to HOMA-IR (r = −0.522, p = 0.002). Insulin resistant subjects showed higher levels of IL6 and lower levels of sIL6R (3.31 ± 0.72 vs. 2.25 ± 0.64 pg/ml, p = 0.020 and 25.3 ± 9.3 vs. 42.5 ± 10.4 ng/ml, p = 0.013, respectively).

Conclusions

In obese children and adolescents, IR is associated with elevated levels of IL-6 and diminished values of sIL-6R.
Literature
1.
go back to reference Weiss R, Dziura J, Burgert TS et al (2004) Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350:2362–2374CrossRefPubMed Weiss R, Dziura J, Burgert TS et al (2004) Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350:2362–2374CrossRefPubMed
2.
go back to reference Viggiano D, De Filippo G, Rendina D et al (2009) Screening of metabolic syndrome in obese children: a primary care concern. J Pediatr Gastroenterol Nutr 49:329–334CrossRefPubMed Viggiano D, De Filippo G, Rendina D et al (2009) Screening of metabolic syndrome in obese children: a primary care concern. J Pediatr Gastroenterol Nutr 49:329–334CrossRefPubMed
3.
go back to reference Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391–3399CrossRefPubMed Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391–3399CrossRefPubMed
4.
go back to reference Galcheva SV, Iotova VM, Yotov YT, Bernasconi S, Street ME (2011) Circulating proinflammatory peptides related to abdominal adiposity and cardiometabolic risk factors in healthy prepubertal children. Eur J Endocrinol 164:553–558CrossRefPubMed Galcheva SV, Iotova VM, Yotov YT, Bernasconi S, Street ME (2011) Circulating proinflammatory peptides related to abdominal adiposity and cardiometabolic risk factors in healthy prepubertal children. Eur J Endocrinol 164:553–558CrossRefPubMed
5.
go back to reference Scheller J, Rose-John S (1997) Interleukin-6 family of cytokines. Annu Rev Immunol 15:797–819CrossRef Scheller J, Rose-John S (1997) Interleukin-6 family of cytokines. Annu Rev Immunol 15:797–819CrossRef
6.
go back to reference Kallen KJ (2002) The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta 1592:323–343CrossRefPubMed Kallen KJ (2002) The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta 1592:323–343CrossRefPubMed
7.
go back to reference Schuett H, Luchtefeld M, Grothusen C et al (2009) How much is too much? Interleukin 6 and its signalling in atherosclerosis. Thromb Haemost 102:215–222PubMed Schuett H, Luchtefeld M, Grothusen C et al (2009) How much is too much? Interleukin 6 and its signalling in atherosclerosis. Thromb Haemost 102:215–222PubMed
8.
go back to reference Weiss TW, Arnesen H, Selijefot I (2013) Components of the Interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial disfunction and arterial stiffness. Metab Clin Exp 62:1008–1013CrossRefPubMed Weiss TW, Arnesen H, Selijefot I (2013) Components of the Interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial disfunction and arterial stiffness. Metab Clin Exp 62:1008–1013CrossRefPubMed
9.
go back to reference Cole TJ, Lobstein T (2012) Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. Pediatr Obes 7:284–294CrossRefPubMed Cole TJ, Lobstein T (2012) Extended international (IOTF) body mass index cut-offs for thinness, overweight and obesity. Pediatr Obes 7:284–294CrossRefPubMed
10.
go back to reference Cole TJ (2002) A chart to link centiles of body mass index, weight and height. Eur J Clin Nutr 56:1194–1199CrossRefPubMed Cole TJ (2002) A chart to link centiles of body mass index, weight and height. Eur J Clin Nutr 56:1194–1199CrossRefPubMed
11.
go back to reference Mattews DR, Hosker JP, Rudeski AS et al (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRef Mattews DR, Hosker JP, Rudeski AS et al (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRef
12.
go back to reference D’Annunzio G, Vanelli M, Pistorio A et al (2009) Insulin resistance and secretion indexes in healthy Italian children and adolescents: a multicentre study. Acta Biomed 80:21–28PubMed D’Annunzio G, Vanelli M, Pistorio A et al (2009) Insulin resistance and secretion indexes in healthy Italian children and adolescents: a multicentre study. Acta Biomed 80:21–28PubMed
13.
go back to reference Fernández-Real JM, Ricart W (2003) Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24:278–301CrossRefPubMed Fernández-Real JM, Ricart W (2003) Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24:278–301CrossRefPubMed
14.
go back to reference Bastard JP, Maachi M, Lagathu C et al (2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17:4–12PubMed Bastard JP, Maachi M, Lagathu C et al (2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17:4–12PubMed
15.
go back to reference Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE (2001) Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 94:14–417 Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE (2001) Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res 94:14–417
16.
go back to reference Stith RD (1994) Luo J Endocrine and carbohydrate responses to interleukin-6 in vivo. Circ Shock 44:210–215PubMed Stith RD (1994) Luo J Endocrine and carbohydrate responses to interleukin-6 in vivo. Circ Shock 44:210–215PubMed
17.
go back to reference Petersen EW, Carey AL, Sacchetti M et al (2005) Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab 288:E155–E162CrossRefPubMed Petersen EW, Carey AL, Sacchetti M et al (2005) Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab 288:E155–E162CrossRefPubMed
18.
go back to reference Bastard JP, Maachi M, Tran Van Nhieu J et al (2002) Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87:2084–2089CrossRefPubMed Bastard JP, Maachi M, Tran Van Nhieu J et al (2002) Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87:2084–2089CrossRefPubMed
19.
go back to reference Mooney RA, Senn J, Cameron S et al (2001) Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 276:25889–25893CrossRefPubMed Mooney RA, Senn J, Cameron S et al (2001) Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 276:25889–25893CrossRefPubMed
20.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed
22.
go back to reference Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C (2005) Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 115:e500–e503CrossRefPubMed Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C (2005) Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 115:e500–e503CrossRefPubMed
Metadata
Title
Interleukin-6, soluble interleukin-6 receptor/interleukin-6 complex and insulin resistance in obese children and adolescents
Authors
G. De Filippo
D. Rendina
F. Moccia
V. Rocco
A. Campanozzi
Publication date
01-03-2015
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 3/2015
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-014-0176-4

Other articles of this Issue 3/2015

Journal of Endocrinological Investigation 3/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.